CRNA raises NOK 620 million, funding through 2030
CRNA raised NOK 620 million to fund circVec R&D and business development through 2030. The company cites circVec technology advances, including up to 60x improved in-vivo gene expression.
Major advances in circVec technology led to up to 60x improved gene expression in vivo, with next-gen designs targeting 200x improvement.
NOK 620 million was raised, securing funding through 2030, enabling expanded R&D and business development, and positioning the company as a leader in circular RN…